Literature DB >> 10327062

Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains.

C Venot1, M Maratrat, V Sierra, E Conseiller, L Debussche.   

Abstract

The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PICG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 transactivation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the aforementioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10327062     DOI: 10.1038/sj.onc.1202539

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor.

Authors:  Gaynor J Bates; Samantha M Nicol; Brian J Wilson; Anne-Marie F Jacobs; Jean-Christophe Bourdon; Julie Wardrop; David J Gregory; David P Lane; Neil D Perkins; Frances V Fuller-Pace
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

2.  Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage.

Authors:  Armin M Gamper; Robert G Roeder
Journal:  Mol Cell Biol       Date:  2008-02-04       Impact factor: 4.272

3.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

4.  Effects of stability on the biological function of p53.

Authors:  Kian Hoe Khoo; Sebastian Mayer; Alan R Fersht
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

5.  Cytokinin Response Factor 5 has transcriptional activity governed by its C-terminal domain.

Authors:  Bernd Striberny; Anthony E Melton; Rainer Schwacke; Kirsten Krause; Karsten Fischer; Leslie R Goertzen; Aaron M Rashotte
Journal:  Plant Signal Behav       Date:  2017-02

6.  Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.

Authors:  Ji-Hyang Ha; Jae-Sun Shin; Mi-Kyung Yoon; Min-Sung Lee; Fahu He; Kwang-Hee Bae; Ho Sup Yoon; Chong-Kil Lee; Sung Goo Park; Yutaka Muto; Seung-Wook Chi
Journal:  J Biol Chem       Date:  2013-01-11       Impact factor: 5.157

7.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 8.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

9.  Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.

Authors:  Chul Won Lee; Munehito Arai; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2009-03-17       Impact factor: 3.162

10.  Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics.

Authors:  Sridharan Rajagopalan; Antonina Andreeva; Daniel P Teufel; Stefan M Freund; Alan R Fersht
Journal:  J Biol Chem       Date:  2009-06-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.